Report Overview

The South Korea Non-Small Cell Lung Cancer (NSCLC) Therapeutics market size stood at around USD 136 million in 2020 and is projected to reach xx million by 2028, exhibiting a CAGR of around xx% during the forecast period.

Lung cancer is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. If untreated, SCLC can be fatal in a few weeks, in contrast to most cases of NSCLC. Approximately 85 % of lung cancer patients in South Korea are affected with non-small cell lung cancer (NSCLC), creating a plethora of opportunities for pharmaceutical companies to expand their portfolios of drugs for this disease.

In 2020, South Koreas NSCLC market experienced a 15% increase compared to the previous year, and the average annual growth rate for the past three years has been 18%.



Market Drivers

South Korea reported 28,651 new cases of Lung Cancer in 2020 and more than 80% of the reported cases were of NSCLC, increasing burden of the disease is a major factor driving the NSCLC market. South Korea's aging population presents drug manufacturers with a vast market, as patients are generally aged 65 or above at the time of diagnosis. In addition to this, the majority of patients are in stage III or IV at the time of diagnosis, where the primary treatment involves drugs. The US Food and Drug Administration (FDA) is implementing an accelerated approval system that shortens clinical trials for serious diseases, this will further propel the market growth.

Pharmaceutical companys R&D efforts will be boosted by South Korea's advanced medical and research infrastructure, combined with the growing biotechnology industry in the forecasted period. Low levels of early diagnosis, lack of a regular screening program are the factors that impede the growth of the market.